Retinal Toxicity Associated with Nab-Paclitaxel and Gemcitabine with SBP-101.
증례보고
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: regular ophthalmology examinations
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Visual acuity (VA) remained stable or slightly worsened from baseline. [CONCLUSION] These cases highlight retinal toxicity of the clinical trial drug nab-paclitaxel and gemcitabine with SBP-101 and the need to monitor these patients with regular ophthalmology examinations.
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.9%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
[PURPOSE] To document retinal toxicity from nab-paclitaxel and gemcitabine with SBP-101, diethyl dihydroxyhomospermine, a polyamine inhibitor for the treatment of metastatic pancreatic adenocarcinoma.
APA
Zhou AZ, Oh JK, et al. (2025). Retinal Toxicity Associated with Nab-Paclitaxel and Gemcitabine with SBP-101.. Retinal cases & brief reports. https://doi.org/10.1097/ICB.0000000000001767
MLA
Zhou AZ, et al.. "Retinal Toxicity Associated with Nab-Paclitaxel and Gemcitabine with SBP-101.." Retinal cases & brief reports, 2025.
PMID
40267384 ↗
Abstract 한글 요약
[PURPOSE] To document retinal toxicity from nab-paclitaxel and gemcitabine with SBP-101, diethyl dihydroxyhomospermine, a polyamine inhibitor for the treatment of metastatic pancreatic adenocarcinoma.
[METHODS] Observational case report.
[RESULTS] Two patients with metastatic pancreatic ductal adenocarcinoma on nab-paclitaxel and gemcitabine with SBP-101 were found to have retina pigmentary changes and retinal pigment epithelium (RPE) mottling. Spectral domain optical coherence tomography (OCT) showed RPE and outer retinal speckled reflectivity in the nasal and superior macula in both eyes. Subsequent follow-up visits demonstrated progression of these findings despite discontinuation of the drug. Visual acuity (VA) remained stable or slightly worsened from baseline.
[CONCLUSION] These cases highlight retinal toxicity of the clinical trial drug nab-paclitaxel and gemcitabine with SBP-101 and the need to monitor these patients with regular ophthalmology examinations.
[METHODS] Observational case report.
[RESULTS] Two patients with metastatic pancreatic ductal adenocarcinoma on nab-paclitaxel and gemcitabine with SBP-101 were found to have retina pigmentary changes and retinal pigment epithelium (RPE) mottling. Spectral domain optical coherence tomography (OCT) showed RPE and outer retinal speckled reflectivity in the nasal and superior macula in both eyes. Subsequent follow-up visits demonstrated progression of these findings despite discontinuation of the drug. Visual acuity (VA) remained stable or slightly worsened from baseline.
[CONCLUSION] These cases highlight retinal toxicity of the clinical trial drug nab-paclitaxel and gemcitabine with SBP-101 and the need to monitor these patients with regular ophthalmology examinations.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Impact of Skeletal Muscle-related Parameters on Survival in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine plus Nab-paclitaxel as First-line Chemotherapy.
- RNA-Micelles as Self-Assembling Structures for Efficient Co-Delivery of Synergistic siRNA and Nucleoside Analogues to Treat CRC Lung Metastasis.
- NQO1 as a predictor of response to adjuvant GemCap treatment for pancreatic cancer.
- Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection.
- Pneumocystis Pneumonia in a Patient Receiving Nab-paclitaxel Plus Gemcitabine for Unresectable Pancreatic Cancer.
- Efficacy and safety of albumin-bound paclitaxel combined with anlotinib and immunotherapy in advanced non-small cell lung cancer with liver metastases: a retrospective study.